CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
Bharat Forge Ltd. 25/07/20241,593.85952.3007/04/2025 -40.25% 256 days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Review
Sagar Bhosale

Review

PRAJ INDUSTRIES 

Ticker : 522205 
FV: Rs2 
52-Week H/L: Rs168/93.45 


We had recommended Praj Industries in volume no. 35, issue no. 27 (dated April 29, 2019), when the scrip was trading at Rs. 143. The company is involved in the business of process and project engineering. Its business lines include ethanol plants, brewery plants, water and wastewater, process equipment and systems, high purity systems, bio-products and also customised research services and solutions (CRSS). We had previously recommended the scrip based on increase in order inflow and government’s focus on augmenting the blending of ethanol. On a consolidated financial front, Praj Industries' revenue has grown by 17.17 per cent to Rs. 294.14 crores in Q2FY20 as against Rs. 251.03 crores posted in Q2FY19. For Q2FY20, PBDT stood at Rs.22.91 crores, up by 21.80 per cent from Rs. 18.81 crores in Q2FY19. The net profit grew substantially by 80.43 per cent in Q2FY20 to Rs 16.13 crores from Rs 8.94 crores in Q1FY19. The company has reported a robust Q2FY20 performance. Hence, we recommend a HOLD.

Previous Article Cadila subsidiary gets USFDA approval for Haloperidol Decanoate Injection
Next Article Diwali Recommendation
Print
257 Rate this article:
No rating
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR